Prostate segmentation Dice similarity coefficient
0.9 Dice
- EndpointSegmentation overlap
- PopulationProstate MR studies in the exact 133-study validation set
- Tested versionCeevra Reveal 3+ release reviewed in K243933
FDA-cleared profile
Ceevra, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))
Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.
Evidence takeaway. Evidence from the reviewed source record: FDA validation covered 133 CT and MR imaging studies and reported structure-specific segmentation results, including prostate MR Dice similarity coefficient 0.90, kidney CT Dice similarity coefficient 0.92 and neurovascular-bundle MR 95th-percentile Hausdorff distance 6.6 mm.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
This field has not been curated yet.
This field has not been curated yet.
0.9 Dice
0.92 Dice
6.6 mm
K243933 FDA 510(k) summary
The FDA summary reports no more than one study per patient and structure-specific metrics across CT and MR models.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Adult CT or MR imaging studies processed by Ceevra models for supported anatomic structures.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933
Source context, not route validation: Ceevra's current workflow page describes IT installation on end-user computers, PACS upload to a cloud workflow, and model viewing on computer, phone, tablet or a medical information system. These are family workflow claims, not an exact K243933 interface specification.
Scope: Product family.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-07 · Ceevra how it works and implementation overview
Source context, not route validation: The FDA summary describes company-generated 3D models delivered to clinician viewers on desktop, mobile, external displays and virtual-reality viewers.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933
Source context, not route validation: Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933
Unresolved route: Interactive 3D models with show, hide, rotate, zoom, pan and measurement controls for prostate, bladder, neurovascular bundles, kidneys, arteries, veins, pulmonary vessels, airways and bronchopulmonary segments as applicable to the model.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Ceevra Reveal 3+, K243933
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Ceevra's current family page describes IT installation on end-user computers and CT or MRI upload from PACS to a cloud workflow; exact K243933 interface details are not established.
product family · checked 2026-09-07The family page describes viewing models on computer, phone, tablet and a medical information system, with structures tailored to the surgery and show/hide controls.
product family · checked 2026-09-07The family page describes annual volume-tiered subscriptions for multiple specialties or hospitals, with no one-time or variable fees; it gives no numeric amount or exact-release contract terms.
product family · checked 2026-09-07Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
A family subscription structure is public, but no numeric price or exact K243933 contract amount was published.
Bounded web search on 2026-10-26 (query: "Ceevra Reveal reimbursement CPT 3D"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
The family page's HIPAA wording is not treated as a current exact-release security attestation.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: regulatoryIdentity, purpose, modality, anatomy
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, intended_use, performance, limitations, implementation
Scope: product_family, commercial_model, implementation, outputs
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Mim Software, Inc.
Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
Arterys, Inc.
Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.
FUJIFILM Healthcare Americas Corporation
Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.
Ziosoft, Inc.
Authorized purpose: Ziostation2 is customer-hardware image-processing software for viewing, quantifying, manipulating, communicating, printing, and managing many radiological image types, with release-specific tools for lung and bronchoscopy planning, cardiac MR T1 mapping, and other advanced visualization.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history